Phase 2 studies of single-agent cladribine in previously treated indolent NHL
| Study . | Cladribine doses . | Histology (%) . | No. of prior therapies . | Response (%) . | Median duration, mo . | ||
|---|---|---|---|---|---|---|---|
| Follicular . | Other . | OR . | CR . | ||||
| Kay et al (1992)26 | A | 65 | 35 | 3 | 43 | 20 | 5 |
| Hickish et al (1993)29 | A | 82 | 18 | 4 | 71 | 29 | 6 |
| Hoffman et al (1994)30 | A | 25 | 75 | 2 | 45 | 15 | 9 |
| Morton et al (1996)27 | B | 67 | 33 | 2 | 63 | 11 | > 13 |
| Liliemark et al (1997)31 | C | 47 | 53 | 2 | 42 | 14 | 9 |
| Robak et al (1997)28 | C | 18 | 82 | 4 | 51 | 13 | > 6 |
| Kong et al (1998)32 | A | 55 | 45 | 3 | 45 | 9 | > 14 |
| Tulpule et al (1998)33 | B | 54 | 46 | 2 | 31 | 12 | > 12 |
| Tondini et al (2000)34 | B | 57 | 43 | 2 | 72 | 38 | Crossover |
| Ogura et al (2004)35 | D | 80 | 20 | 2 | 58 | 14 | 8 |
| Tobinai et al (2009)36 | C | 72 | 28 | 2 | 50 | 11 | > 12 |
| Study . | Cladribine doses . | Histology (%) . | No. of prior therapies . | Response (%) . | Median duration, mo . | ||
|---|---|---|---|---|---|---|---|
| Follicular . | Other . | OR . | CR . | ||||
| Kay et al (1992)26 | A | 65 | 35 | 3 | 43 | 20 | 5 |
| Hickish et al (1993)29 | A | 82 | 18 | 4 | 71 | 29 | 6 |
| Hoffman et al (1994)30 | A | 25 | 75 | 2 | 45 | 15 | 9 |
| Morton et al (1996)27 | B | 67 | 33 | 2 | 63 | 11 | > 13 |
| Liliemark et al (1997)31 | C | 47 | 53 | 2 | 42 | 14 | 9 |
| Robak et al (1997)28 | C | 18 | 82 | 4 | 51 | 13 | > 6 |
| Kong et al (1998)32 | A | 55 | 45 | 3 | 45 | 9 | > 14 |
| Tulpule et al (1998)33 | B | 54 | 46 | 2 | 31 | 12 | > 12 |
| Tondini et al (2000)34 | B | 57 | 43 | 2 | 72 | 38 | Crossover |
| Ogura et al (2004)35 | D | 80 | 20 | 2 | 58 | 14 | 8 |
| Tobinai et al (2009)36 | C | 72 | 28 | 2 | 50 | 11 | > 12 |
A indicates 0.1 mg/kg per day as continuous intravenous infusion for 7 days; B, 0.14 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days; C, 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days; and D, 0.09 mg/kg per day as continuous intravenous infusion for 7 days.